Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of APL-1202 for free-living amoeba infection
CTR20251793Phase 2Active
- Sponsor
- Aurobindo Pharma Limited
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APL-1202 + APL-1501 in Free-Living Amebic Infection, amebic encephalitis (AE), sponsored by Aurobindo Pharma Limited. Started May 2026; status: active.
02
Drugs
APL-1202 + APL-1501
03
Conditions
Free-Living Amebic Infectionamebic encephalitis (AE)
Beyond the preview
Go deeper on CTR20251793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251793.